RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Nektar Therapeutics ROCE 2024

Nektar Therapeutics ROCE

-1.03

Nektar Therapeutics Dividend yield

Ticker

NKTR

ISIN

US6402681083

WKN

165417

In 2024, Nektar Therapeutics's return on capital employed (ROCE) was -1.03, a 57.5% increase from the -0.66 ROCE in the previous year.

Nektar Therapeutics Aktienanalyse

What does Nektar Therapeutics do?

"Answer: Nektar Therapeutics is an American biopharmaceutical company based in San Francisco, specializing in the discovery and development of drugs for the treatment of cancer, autoimmune, and chronic metabolic diseases. The company was founded in 1990 by CEO Howard Robin and his team, initially focused on researching new technologies for drug development and later shifted to developing drugs for cancer therapy. Nektar Therapeutics has a unique business model that involves partnering with major pharmaceutical companies and other partners to develop a wide range of products, which are then licensed to these partners for commercialization and distribution. The company operates in several sectors, including oncology, pain management, autoimmune diseases, and metabolic diseases. Its important products include Movantik for opioid-induced constipation and ONZEALD for pancreatic cancer treatment. Nektar Therapeutics has made significant progress in developing immunoncology drugs, with potential projects such as NKTR-214 for advanced skin cancers. With its leading position in innovative drug development and strategic partnerships, the company has the potential to become a major player in cancer therapy." Nektar Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Nektar Therapeutics's Return on Capital Employed (ROCE)

Nektar Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Nektar Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Nektar Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Nektar Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Nektar Therapeutics Stock

What is the ROCE (Return on Capital Employed) of Nektar Therapeutics this year?

The ROCE of Nektar Therapeutics is -1.03 undefined this year.

How has the ROCE (Return on Capital Employed) of Nektar Therapeutics developed compared to the previous year?

The ROCE of Nektar Therapeutics has increased by 57.5% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Nektar Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Nektar Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Nektar Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Nektar Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Nektar Therapeutics impact the company?

An increase in the ROCE of Nektar Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Nektar Therapeutics affect the company?

A decrease in ROCE of Nektar Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Nektar Therapeutics?

Some factors that can affect Nektar Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Nektar Therapeutics so important for investors?

The ROCE of Nektar Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Nektar Therapeutics take to improve the ROCE?

To improve the ROCE, Nektar Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Nektar Therapeutics pay?

Over the past 12 months, Nektar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nektar Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nektar Therapeutics?

The current dividend yield of Nektar Therapeutics is .

When does Nektar Therapeutics pay dividends?

Nektar Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nektar Therapeutics?

Nektar Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nektar Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nektar Therapeutics located?

Nektar Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nektar Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nektar Therapeutics from 5/23/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/23/2024.

When did Nektar Therapeutics pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of Nektar Therapeutics in the year 2023?

In the year 2023, Nektar Therapeutics distributed 0 USD as dividends.

In which currency does Nektar Therapeutics pay out the dividend?

The dividends of Nektar Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Nektar Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Nektar Therapeutics

Our stock analysis for Nektar Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nektar Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.